Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | DS-7300: the B7-H3 targeting anti-body drug conjugate

Toshihiko Doi • 10 Sep 2022
ESMO 2022
General Antibodies DS-7300

Toshihiko Doi, MD, PhD, National Cancer Center Hospital East, Chiba, Japan, provides an overview of DS-7300, an antibody-drug conjugate (ADC) with an exatecan derivative payload targeting B7-H3, which is overexpressed in a wide range of cancers, contributing to cancer progression and progression. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Toshihiko Doi

1:17
DS-7300 demonstrates durable antitumor activity in advanced solid tumors
Toshihiko Doi • 10 Sep 2022

Related Videos

1:56
Phase I trial of trastuzumab deruxtecan and neratinib in HER2-altered tumors
Haeseong Park • 8 Apr 2024
2:45
Remaining challenges in treating solid tumors with CAR-Treg therapy
Leonardo Ferreira • 8 Apr 2024
2:01
Engineering chimeric antigen receptor regulatory T cells for treating cancer
Leonardo Ferreira • 8 Apr 2024
0:59
What challenges are there in using CAR-T cells for solid tumors?
Leonardo Ferreira • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals